CYTOKINETICS, INCORPORATED Excess Tax Benefit from Share-based Compensation, Financing Activities
CYTOKINETICS, INCORPORATED (CYTK) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of -$20.00 thousand for the 12-month period ending 2010-12-31, per its 10-K filed 2013-03-15.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2013-03-15
- CYTOKINETICS, INCORPORATED excess tax benefit from share-based compensation, financing activities for the quarter ending 2010-12-31 was $0.00.
- CYTOKINETICS, INCORPORATED excess tax benefit from share-based compensation, financing activities for fiscal 2010 was -$20.00K, a 200.00% decline from fiscal 2009.
- CYTOKINETICS, INCORPORATED excess tax benefit from share-based compensation, financing activities for fiscal 2009 was $20.00K.
| Period end | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 9 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month |
|---|---|---|---|
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | -$20.00K 10-K · filed 2013-03-15 | |
| 2010-09-30 | -$20.00K 10-Q · filed 2011-11-04 | ||
| 2009-12-31 | $20.00K 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |